Colorectal cancer is a common mortal disease and second leading cause of cancer death in both sexes; namely it caused 10 to 11% of cancer deaths overall.[@ref1] Former studies have indicated some mutations in the mtDNA in different human cancers.[@ref2]--[@ref4] Mitochondrial genome in the human cells is a 16.6 kb in size and it is a closed-circular, double-stranded DNA molecule. It is a genetic lo-cus independent of the nuclear genome. The only 13 polypeptides encoded by human mtDNA involved in oxidative phosphorylation (OXPHOS) and 2 rRNAs, and a set of 22 tRNAs that are essential for protein synthesis in mitochondria are encoded by mtDNA.[@ref5] All of the mitochondrial protein coding genes en-code subunits of the OXPHOS enzymes that are responsible for the energy generation pathway.

Reduced nicotinamide-adenine dinucleotide dehydrogenase or complex I NADH has the most subunits encoded by mtDNA; therefore it is exceptionally susceptible to defects if mtDNA mutations are happened.

One of the major cellular generators of reactive oxygen species (ROS) is the electron transport chain of mitochondrial, which include the hydroxyl free radical (OH-) hydrogen peroxide (H~2~O~2~), and superoxide. Mutations in mtDNA has been suggested to have the ability for actuating an increase in ROS level, followed by deterioration of oxidative phosphorylation and mitochondrial respiration which leads to oxidative stress that can modify the DNA. Higher amounts of superoxide production in vivo have also been demonstrated in the cells with complex I deficiency.[@ref6][@ref7]

In particular, the production of ROS probably occurs when complex I activity is depraved; as scientists have reported not only it happened in the cells carrying the T9957C COX III mutation, but also in the cells carrying the G3460A ND1 mutation,[@ref8] A3243G in Leu tRNA, A8344G in Lys tRNA[@ref9] and T8993G mutations.[@ref10] Additionally, the existence of particular mutation patterns has been indicated in the mtDNA of various cancers by researchers.[@ref11][@ref12] Abnormal metabolic and apoptotic procedures in neoplastic cells are considered as consequence of these mutations in some cases.[@ref13] Certainly, mutational hot spots in the NADH dehydrogenase subunits 3, 4 and 5 from complex I, were determined in renal and colorectal tumors.[@ref12][@ref14] To investigate mtDNA mutation of colorectal cancer, presence of mutations in one of the important mtDNA genes was checked, namely MTND1 gene, in cancerous tissues with comparison to noncancerous adjacent tissues from the CRC patients.

Method {#sec1-1}
======

Samples Preparation and DNA Extraction {#sec2-1}
--------------------------------------

Thirty tissue blocks of colorectal cancer patients were collected from the Baghiyatallah Hospital in Tehran from 2005 to 2007. The tissues were fixed in formalin and embedded in paraffin. The patients consisted of 13 and 17 women and men, respectively. The age range of the cases was 34-78; their mean ± SD of their age was 54.6 ± 13.1. In this study existence of mutations in tumoral tissues is compared to its existence in non-tumoral adjacent tissues of the same samples. Five μm sections of samples were prepared on slides then were deparaffinized and stained with hematoxylin and eosin (H & E) using standard operating procedure for pathological diagnosis.

All tumoral tissues and adjacent non-tumoral tissue specimens were confirmed by pathological diagnosis. Based on the patients file the patients in this study have not received chemotherapy or radiation therapy before surgery Formalin-fixed, paraffin embedded samples according to standard methods.[@ref15] The patients were informed about the aims of the study and then gave their informed consents for the genetic analysis.

Sequence Analysis {#sec2-2}
-----------------

The mitochondrial ND1 gene from each sample was amplified by PCR (mt3187F primer 5'-CTCAACTTAGTATTATACCC -3', located at 3187-3206 bp; and mt4650R primer 5'-GGAAATACTTGATGGCAGCT -3' located at 4650-4631 bp). The amplified sequence with this primer is a 1463 bp in size. The nucleotides of this amplified sequence were directly determined by automated sequencing using ABI 3700 machines.

A multiple sequence alignment was made between the obtained mtDNA sequences interface, CLUSTAL X, with comparison to rCRS ([http:/www.gen.emory.edu/mitomap/mitoseq. html](http:/www.gen.emory.edu/mitomap/mitoseq.html)).

PCR-RFLP {#sec2-3}
--------

A 384 bp PCR fragment was amplified from mitochondrial ND1 gene for using in RFLP analysis. The following primer pair was used for amplifying the requested PCR fragment mt4491F located at

4491-4510 (5'-GTCATCTACTCTACCATCTT-3') and mt4144R located at 4144-4126 (5'-TCGGGGGTATGCTGTTCG-3'). The 384 bp amplified sequence was digested with NlaIII (Fermentas, Germany). The T→C variant at nt 4216 are used for RFLP method, because this variation created a recognition site for the restriction endonuclease NlaIII. The recognition site of NlaIII is 5'-CATG\^-3'. PCR product was digested overnight at 37°C; mutant samples were cut into two 291 bp and 93 bp fragments but there was not any cut points in normal samples.

Statistical Analysis {#sec2-4}
--------------------

Fisher\'s exact probability test was used in order to compare qualitative variables. A p value ≤ 0.05 has been considered statistically significant correlation.

Results {#sec1-2}
=======

Mitochondrial genome, as former studies suggested, is particularly susceptible to mutations. Insomuch, the generation of high level reactive oxygen species (ROS) in this organelle,[@ref16]--[@ref18] associated with a low level of mismatch repair gene[@ref19]--[@ref21] in the mitochondrial genome.

The presented result revealed a T4216C point mutation in 8 samples out of 30 CRC samples, which cause an amino acid change of Tyrosin with the amino acid Histidin (Y→H) in MTND1 gene. Furthermore the T3290C, T3456C, A3480G, C3622T, C3741T, T3777C and T3847C point mutations were found in 7 of the 30 patients. Each of mentioned point mutations was found and detected in one sample [Table 1](#T1){ref-type="table"}. None of the mutations were detected in adjacent normal tissues as compared with tumoral tissue samples of the patients.

The T4216C mutation was reported in LHON and insulin resistance diseases.[@ref22]--[@ref24]

The T4216C mutation was determined in 8 patients out of 30 CRC patients; therefore the prevalence of this mutation affirming homoplasty is determined to be 27% in these examined patients ([Figure 1](#F1){ref-type="fig"}). The existence of T4216C mutation was found to be significantly different (p ≤ 0.05) between patient\'s tumoral tis-sue and their adjusted normal tissue ([Table 1](#T1){ref-type="table"}).

![Part of alignment of sequences for determination of the mutation T4216C](JRMS-16-50-g001){#F1}
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The identified mutations of MTND1 gene in colorectal cancer patient
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Figure [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} shows the mutation at nucleotide position T4216C of mtDNA in patients who carry the mutation and those who are de-void of mutation, respectively.

![Detection of somatic mtDNA mutations in colorectal cancer patient Arrow shows the mutated amino acid](JRMS-16-50-g003){#F2}

![Sequences of non-tumoral adjacent tissues from the same CRC patient devoid of T4216C mutations](JRMS-16-50-g004){#F3}

Discussion {#sec1-3}
==========

Based on the present results, seven out of eight mutations were found in the coding region. All these mutations were T/C transitions while only one A/G transvertion was detected. Five of them did not result in amino acid modifications. One of them was seen in non-coding region. The C3622T consequences Leu(2) to Leu(1) amino acid and the T4216C mutation that was detected in 27% (8 patients out of 30 patients) of tested samples, resulted in the sub-stitution of Tyrosin with the amino acid Histidin. This T4216C variation has been observed and was reported in LHON[@ref22] and insulin resistance diseases.[@ref23]

It was suggested that tumoral cells with indistinguishable nuclei accompanying mitochondrial mutations grow faster than cells destitute of mitochondrial mutations.[@ref25]

The contribution of mtDNA mutations to the malignant phenotype of tumor cells in most cases still remains unknown and need more investigations. But it is to speculate that, existence of mtDNA mutations in cancer cells is consequent of mitochondrial DNA intrinsic susceptibility to damage because of ROS gen-eration in mitochondria. On the other hand, it is demonstrated that tumors with mutation also significantly generate more ROS (confirmed by dihydroethidium staining).[@ref25] There is also another report that speculate probable role of other mitochondrial mutations with known OXPHOS defects in tumorgenesis.[@ref26]

Mitochondrial DNA abnormal variations appear to be a common shape of malignant cells. Abnormal expression of mtDNA-encoded proteins caused by mutation, deletion or insertion in mtDNA has been reported in various solid tumors.[@ref27]--[@ref31]. Detection of cancer specific mtDNA abnormalities has increased within recent years.

It is difficult to speculate about the role of this mutation in CRC. LHON mutations were shown to affect complex I in mitochondria and other investigators found other mutations in different parts of this gene. To show pathogenicity of this mutation or find its role in cancer, more investigations particularly in mtDNA of colorectal cancer patients are needed.

Conclusions {#sec1-4}
===========

Based on the presented results it is suggested that a high frequency of somatic alterations of mtDNA may occur during the carcinogenesis and/or the progression of colorectal cancer. The molecular mechanisms by which mtDNA alterations or mitochondrial OXPHOS defects influence tumor formation and cancer progression is unclear and need further investigation. Based on the mtDNA mutation pattern observed in this study and other previously studies, it is believed that looking for somatic mutations in mtDNA, would be one of the diagnostic values in early detection of cancer.
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